FDA has provided opportunities for R&D in rare disease, although recent developments have caused significant setbacks to occur. The rare disease space has always been uniquely difficult for drug ...
Icotyde is the first targeted oral peptide IL‑23 receptor antagonist, designed to interrupt a core psoriasis inflammatory axis while avoiding injection-based administration typical of IL‑23 biologics.
Founder, Infinitus, notes the the emerging themes at Access USA 2026, including regulatory shifts, the collapse of the traditional hub model, and the proliferation of fragmented AI point solutions. In ...
Are they destined to change the future of pharma? Nominate a colleague with impressive leadership and career intentions ...
Launched in January, TrumpRx.gov is part of a series of most-favored-nation deals struck between the Trump administration and ...
Matt Turner, President of Patient Affordability, Paysign discusses the evolving financial threats to pharmaceutical ...
War in the Middle East disrupts pharmaceutical supply chains in the Gulf region, forcing drugmakers to reroute shipments of ...
Matthew Turner, President of Patient Affordability, Paysign, touches on how evolving payer tactics appear to be pushing ...
Matthew Turner, President of Patient Affordability, Paysign discusses how next-generation copay assistance appears to be less about consolidating services under one vendor and more about assembling ...
Vera Pomerantseva, Director of Product Management for RBQM, eClinical Solutions, touched on AI's growing role in clinical ...
Excalipoint Therapeutics closed an oversubscribed $68.7 million seed financing, one of the largest early-stage rounds for a Chinese biotechnology company, to advance its pipeline of six T-cell engager ...
In today's Pharmaceutical Executive Daily, ongoing conflict in the Middle East is straining pharmaceutical supply routes to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results